Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT

Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT
costimulatory proteins as a novel vaccine approach for cancer immunotherapy

Primary tumor cells genetically modified to express a collection of immunological
ligands on their surface may have the utility as therapeutic autologous cancer
vaccines. However, genetic modification of primary tumor cells is not only cost,
labor and time intensive, but also has safety repercussions. As an alternative,
we developed the ProtEx technology that involves generation of immunological
ligands with core streptavidin (SA) and their display on biotinylated cells in a
rapid and efficient manner. We herein demonstrate that TC-1 tumor cells can be
rapidly and efficiently engineered to codisplay on their surface two costimulatory proteins, SA-4-1BBL and SA-LIGHT, simultaneously. Vaccination with irradiated TC-1 cells codisplaying both chimeric proteins showed 100% efficacy in a prophylactic and >55% efficacy in a therapeutic tumor setting. In
contrast, vaccination with TC-1 cells


Cancer Gene Therapy 17, 730-741 (October 2010) |
doi:10.1038/cgt.2010.29